Dodam John R, Cohn Leah A, Durham Harris E, Szladovits Balazs
Department of Veterinary Medicine and Surgery, College of Veterinary Medicine, University of Missouri, 379 East Campus Drive, Columbia, MO 65211, USA.
Vet Anaesth Analg. 2004 Apr;31(2):129-37. doi: 10.1111/j.1467-2987.2004.00164.x.
To determine if chronic selegiline HCl administration affects the cardiopulmonary response to medetomidine, oxymorphone, or butorphanol in dogs.
Prospective randomized experimental study.
Twenty-eight adult, random source, hound dogs weighing 21-33 kg.
Dogs were assigned to the following treatment groups: selegiline + medetomidine (MED; n = 6); placebo + MED (n = 6), selegiline + oxymorphone (OXY; n = 6); placebo + OXY (n = 6); selegiline + butorphanol (BUT; n = 7) or placebo + BUT (n = 6). Nine dogs were treated with two of the three pre-medicants. Dogs were treated with selegiline (1 mg kg(-1) PO, q 24 hours) or placebo for at least 44 days prior to pre-medicant administration. On the day of the experiment, arterial blood for blood gas analysis, blood pressure measurements, ECG, cardiac ultrasound (mM-mode, 2-D, and continuous wave Doppler), and behavioral observations were obtained by blinded observers. An IV injection of MED (750 micro g m(-2)), OXY (0.1 mg kg(-1)) or BUT (0.4 mg kg(-1)) was given. Cardiopulmonary and behavioral data were collected at 1, 2, 5, 15, 30, and 60 minutes after injection.
Selegiline did not modify responses to any of the pre-medicant drugs. Medetomidine caused a significant decrease in heart rate (HR), cardiac output (CO), and fractional shortening (FS). Mean arterial pressure (MAP), systemic vascular resistance (SVR), and central venous pressure (CVP) were increased. Level of consciousness and resistance to restraint were both decreased. Oxymorphone did not affect MAP, CO, CVP, or SVR, but RR and PaCO(2) were increased. Level of consciousness and resistance to restraint were decreased. BUT decreased heart rate at 1 and 5 minutes. All other cardiovascular parameters were unchanged. BUT administration was associated with decreased arterial pH and increased PaCO(2). BUT decreased level of consciousness and resistance to restraint.
Although pre-medicants themselves altered cardiopulmonary and behavioral function, selegiline did not affect the response to medetomidine, oxymorphone, or butorphanol in this group of normal dogs.
确定长期给予盐酸司来吉兰是否会影响犬对美托咪定、羟吗啡酮或布托啡诺的心肺反应。
前瞻性随机实验研究。
28只成年、随机来源的猎犬，体重21 - 33千克。
将犬分为以下治疗组：司来吉兰 + 美托咪定（MED组；n = 6）；安慰剂 + 美托咪定（n = 6），司来吉兰 + 羟吗啡酮（OXY组；n = 6）；安慰剂 + 羟吗啡酮（n = 6）；司来吉兰 + 布托啡诺（BUT组；n = 7）或安慰剂 + 布托啡诺（n = 6）。9只犬接受了三种预处理药物中的两种治疗。在给予预处理药物前，犬接受司来吉兰（1毫克/千克口服，每24小时一次）或安慰剂治疗至少44天。在实验当天，由不知情的观察者采集动脉血用于血气分析、测量血压、进行心电图、心脏超声检查（M型、二维和连续波多普勒）以及行为观察。静脉注射MED（750微克/平方米）、OXY（0.1毫克/千克）或BUT（0.4毫克/千克）。在注射后1、2、5、15、30和60分钟收集心肺和行为数据。
司来吉兰未改变对任何一种预处理药物的反应。美托咪定导致心率（HR）、心输出量（CO）和缩短分数（FS）显著降低。平均动脉压（MAP）、全身血管阻力（SVR）和中心静脉压（CVP）升高。意识水平和对约束的抵抗能力均降低。羟吗啡酮未影响MAP、CO、CVP或SVR，但呼吸频率（RR）和动脉血二氧化碳分压（PaCO₂）升高。意识水平和对约束的抵抗能力降低。BUT在1和5分钟时使心率降低。所有其他心血管参数均无变化。给予BUT与动脉血pH值降低和PaCO₂升高有关。BUT降低了意识水平和对约束的抵抗能力。
尽管预处理药物本身改变了心肺和行为功能，但在这组正常犬中，司来吉兰并未影响对美托咪定、羟吗啡酮或布托啡诺的反应。
